Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

64
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
64
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

3.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

571
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
571

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation.

Heart rhythm O2·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Surface Electrocardiographic Parameters of Children and Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder in an Ambulatory Community Pediatric Center: A Focus on Cardiac Repolarization Electrocardiogram Intervals.

Journal of child and adolescent psychopharmacology·2021
Same author

Immunoglobulin Free Light Chains as Inflammatory Biomarkers of Atrial Fibrillation.

Circulation. Arrhythmia and electrophysiology·2020
Same author

Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis.

Clinical immunology (Orlando, Fla.)·2020
Same author

Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects.

Clinical therapeutics·2019

Related Experiment Video

Updated: Mar 8, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

14.5K

Antimicrobials and QT prolongation.

Jay W Mason

    The Journal of Antimicrobial Chemotherapy
    |February 5, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Ketolide antibiotics, like solithromycin, show minimal QT-prolonging effects, unlike macrolides. This makes ketolides a safer choice for patients at risk of cardiac arrhythmias.

    More Related Videos

    Quantification of Violacein in Chromobacterium violaceum and Its Inhibition by Bioactive Compounds
    07:13

    Quantification of Violacein in Chromobacterium violaceum and Its Inhibition by Bioactive Compounds

    Published on: August 8, 2025

    1.8K
    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
    11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    5.5K

    Related Experiment Videos

    Last Updated: Mar 8, 2026

    Electrocardiogram Recordings in Anesthetized Mice using Lead II
    04:16

    Electrocardiogram Recordings in Anesthetized Mice using Lead II

    Published on: June 20, 2020

    14.5K
    Quantification of Violacein in Chromobacterium violaceum and Its Inhibition by Bioactive Compounds
    07:13

    Quantification of Violacein in Chromobacterium violaceum and Its Inhibition by Bioactive Compounds

    Published on: August 8, 2025

    1.8K
    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
    11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    5.5K

    Area of Science:

    • Pharmacology
    • Cardiology
    • Microbiology

    Background:

    • Antimicrobials, particularly macrolides, pose a significant risk for cardiac arrhythmias due to QT prolongation.
    • This risk stems from their interaction with the IKr potassium channel and potential drug metabolism interference.
    • Practitioners often overlook the cardiac risks associated with antimicrobial prescribing.

    Purpose of the Study:

    • To investigate the QT-prolonging effects of solithromycin, a novel ketolide antibiotic.
    • To compare the cardiac safety profile of ketolides versus traditional macrolides.
    • To highlight the need for increased awareness regarding antimicrobial-induced cardiac arrhythmias.

    Main Methods:

    • Evaluation of solithromycin's effect on the QT interval.
    • Comparison of QT effects among solithromycin, other ketolides, and macrolides.
    • Review of antimicrobial mechanisms affecting cardiac ion channels and drug metabolism.

    Main Results:

    • Solithromycin demonstrated a lack of significant QT-prolonging effect, contrary to expectations for macrolide antibiotics.
    • Other tested ketolides also exhibited minimal QT prolongation.
    • The keto substitution in ketolides appears to be the structural basis for their improved cardiac safety.

    Conclusions:

    • Ketolides, including solithromycin, represent a safer alternative to macrolides for patients susceptible to QT prolongation and cardiac arrhythmias.
    • Enhanced medical education is crucial to address the underestimation of antimicrobial cardiac risks.
    • Consideration of ketolides is recommended when macrolides are indicated in at-risk patients.